Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years

被引:185
作者
Dolle, Jessica M. [1 ]
Daling, Janet R. [1 ]
White, Emily [1 ,3 ]
Brinton, Louise A. [4 ]
Doody, David R. [1 ]
Porter, Peggy L. [2 ]
Malone, Kathleen E. [1 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA
关键词
ORAL-CONTRACEPTIVE USE; PROGESTERONE-RECEPTOR STATUS; GENE-EXPRESSION PATTERNS; ESTROGEN-RECEPTOR; HORMONE-RECEPTOR; YOUNG-WOMEN; ADJUVANT CHEMOTHERAPY; REPRODUCTIVE FACTORS; MOLECULAR SUBTYPES; AFRICAN-AMERICAN;
D O I
10.1158/1055-9965.EPI-08-1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known about the etiologic profile of triple-negative breast cancer (negative for estrogen receptor/progesterone receptor/human epidermal growth factor), a breast cancer subtype associated with high mortality and inadequate therapeutic options. We undertook this study to assess the risk for triple-negative breast cancer among women 45 years of age and younger in relation to demographic/lifestyle factors, reproductive history, and oral contraceptive use. Study participants were ascertained in two previous population-based, case-control studies. Eligible cases included all primary invasive breast cancers among women ages 20 to 45 years in the Seattle-Puget Sound area, diagnosed between January 1983 and December 1992, for whom complete data was obtained for estrogen receptor, progesterone receptor, and human epidermal growth factor status (n = 897; including n = 187 triple-negative breast cancer cases). Controls were age matched and ascertained via random digit dialing. Oral contraceptive use l year was associated with a 2.5-fold increased risk for triple-negative breast cancer (95% confidence interval, 1.4-4.3) and no significantly increased risk for non-triple-negative breast cancer (P-heterogeneity = 0.008). Furthermore, the risk among oral contraceptive users conferred by longer oral contraceptive duration and by more recent use was significantly greater for triple-negative breast cancer than non-triple-negative breast cancer (P-heterogeneity = 0.02 and 0.01, respectively). Among women :<= 40 years, the relative risk for triple-negative breast cancer associated with oral contraceptive use >= 1 year was 4.2 (95% confidence interval, 1.9-9.3), whereas there was no significantly increased risk with oral contraceptive use for non-triple-negative breast cancer among women <= 40 years, nor for triplenegative breast cancer or non-triple-negative breast cancer among women 41 to 45 years of age. In conclusion, significant heterogeneity exists for the association of oral contraceptive use and breast cancer risk between triple-negative breast cancer and non-triple-negative breast cancer among young women, lending support to a distinct etiology. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1157-66)
引用
收藏
页码:1157 / 1166
页数:10
相关论文
共 54 条
[1]  
Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
[2]   Breast cancers among very young premenopausal women (United States) [J].
Althuis, MD ;
Brogan, DD ;
Coates, RJ ;
Daling, JR ;
Gammon, MD ;
Malone, KE ;
Schoenberg, JB ;
Brinton, LA .
CANCER CAUSES & CONTROL, 2003, 14 (02) :151-160
[3]  
[Anonymous], 2008, Modern epidemiology
[4]  
Armes JE, 1999, CANCER RES, V59, P2011
[5]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[6]   ORAL-CONTRACEPTIVES AND BREAST-CANCER RISK AMONG YOUNGER WOMEN [J].
BRINTON, LA ;
DALING, JR ;
LIFF, JM ;
SCHOENBERG, JB ;
MALONE, KE ;
STANFORD, JL ;
COATES, RJ ;
GAMMON, MD ;
HANSON, L ;
HOOVER, RN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :827-835
[7]   Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age [J].
Britton, JA ;
Gammon, MD ;
Schoenberg, JB ;
Stanford, JL ;
Coates, RJ ;
Swanson, CA ;
Potischman, N ;
Malone, KE ;
Brogan, DJ ;
Daling, JR ;
Brinton, LA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (06) :507-516
[8]  
Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
[9]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[10]  
Clarke M, 1998, LANCET, V351, P1451